1270 related articles for article (PubMed ID: 26582965)
1. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut.
Michielan A; D'Incà R
Mediators Inflamm; 2015; 2015():628157. PubMed ID: 26582965
[TBL] [Abstract][Full Text] [Related]
2. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
[TBL] [Abstract][Full Text] [Related]
3. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics.
Linskens RK; Huijsdens XW; Savelkoul PH; Vandenbroucke-Grauls CM; Meuwissen SG
Scand J Gastroenterol Suppl; 2001; (234):29-40. PubMed ID: 11768558
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
[TBL] [Abstract][Full Text] [Related]
5. Microbiota and mucosal defense in IBD: an update.
Stange EF; Schroeder BO
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):963-976. PubMed ID: 31603356
[No Abstract] [Full Text] [Related]
6. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
[TBL] [Abstract][Full Text] [Related]
7. A spotlight on intestinal permeability and inflammatory bowel diseases.
Rath T; Atreya R; Neurath MF
Expert Rev Gastroenterol Hepatol; 2023; 17(9):893-902. PubMed ID: 37606514
[TBL] [Abstract][Full Text] [Related]
8. Talk about micromanaging! Role of microRNAs in intestinal barrier function.
Al-Sadi R; Engers J; Abdulqadir R
Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G170-G174. PubMed ID: 32658620
[TBL] [Abstract][Full Text] [Related]
9. Probiotics and inflammatory bowel diseases.
Bai AP; Ouyang Q
Postgrad Med J; 2006 Jun; 82(968):376-82. PubMed ID: 16754706
[TBL] [Abstract][Full Text] [Related]
10. A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice.
Sydora BC; Tavernini MM; Doyle J; Fedorak RN
Inflamm Bowel Dis; 2006 Aug; 12(8):750-7. PubMed ID: 16917231
[TBL] [Abstract][Full Text] [Related]
11. Intestinal barrier dysfunction in inflammatory bowel diseases.
McGuckin MA; Eri R; Simms LA; Florin TH; Radford-Smith G
Inflamm Bowel Dis; 2009 Jan; 15(1):100-13. PubMed ID: 18623167
[TBL] [Abstract][Full Text] [Related]
12. Pathway-based approaches to the treatment of inflammatory bowel disease.
Bamias G; Pizarro TT; Cominelli F
Transl Res; 2016 Jan; 167(1):104-15. PubMed ID: 26408803
[TBL] [Abstract][Full Text] [Related]
13. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function.
Schoultz I; Keita ÅV
Cells; 2019 Feb; 8(2):. PubMed ID: 30813280
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases.
Hyun CK
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502047
[TBL] [Abstract][Full Text] [Related]
15. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease.
Kiesslich R; Duckworth CA; Moussata D; Gloeckner A; Lim LG; Goetz M; Pritchard DM; Galle PR; Neurath MF; Watson AJ
Gut; 2012 Aug; 61(8):1146-53. PubMed ID: 22115910
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut.
Garcia-Carbonell R; Yao SJ; Das S; Guma M
Front Immunol; 2019; 10():1094. PubMed ID: 31164887
[TBL] [Abstract][Full Text] [Related]
17. Importance of disrupted intestinal barrier in inflammatory bowel diseases.
Salim SY; Söderholm JD
Inflamm Bowel Dis; 2011 Jan; 17(1):362-81. PubMed ID: 20725949
[TBL] [Abstract][Full Text] [Related]
18. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
Merga Y; Campbell BJ; Rhodes JM
Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
[TBL] [Abstract][Full Text] [Related]
19. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
20. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1.
Hartwig O; Loretz B; Nougarede A; Jary D; Sulpice E; Gidrol X; Navarro F; Lehr CM
J Control Release; 2022 May; 345():646-660. PubMed ID: 35339579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
